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Abstract
Background: The assessment of TP53 mutational status is becoming a routine clinical practice for chronic lymphocytic
leukemia patients (CLL). A broad spectrum of molecular techniques has been employed so far, including both direct
Sanger sequencing and next generation sequencing. Oxford Nanopore Technologies recently released the MinION an
USB-interfaced sequencer. In this paper we report our experience, with the MinION technology for the detection of the
TP53 gene mutation in CLL patients.
Twelve CLL patients at diagnosis were included in this study. All except one patient showed the TP53 gene deletion in
Fluorescence in situ hybridization experiments.
Patients were investigated for TP53 mutation by Sanger and by MinION sequencing.
Analysis by Sanger was performed according with the IARC protocol.
Analysis by MinION was performed adopting a strategy based on long template PCR, read error correction, and post
variant calling filtering.
Results: Due to the high error rate of nanopore technology, sequence data were both used directly and before
correction with two different in silico methods: ALEC and nanocorrect. A mean error rate of 15 % was detected before
correction that was reduced to 4-5 % after correction.
Analysis by Sanger sequencing was able to detect four patients mutated for TP53. MinION analysis detected one more
mutated patient previously not detected from Sanger.
Conclusion: In our hands, the Nanopore technology shows correlation with Sanger sequencing but more sensitive,
manageable and less expensive, and therefore has proven to be a useful tool for TP53 gene mutation detection.
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Background
Tumor-suppressor p53 gene (TP53) maps to chromo-
some band 17p13 and is pivotal for genome integrity.
TP53 encodes for the p53 protein, a transcription factor
involved in essential cell functions, such as DNA repair,
cell cycle control, apoptosis, aging, and stemness [1, 2].
Aberrant p53 function, due to 17p deletion (del(17p))
and/or TP53 mutation, is associated with poor prognosis
in chronic lymphocytic leukemia (CLL) patients [3–5].
Alterations of TP53 occur in about 10 % of untreated
CLL patients [6, 7], but up to 50 % in relapsed or refrac-
tory cases [8, 9]. Furthermore, over 80 % of cases har-
boring del(17p) also carry TP53 mutations in the
remaining allele [10, 11]. The frequency of mutations
lacking del(17p) varies among different studies depend-
ing on the patient cohort and the methodology used, but
in general it accounts for about 30 % of all TP53 defects,
while sole 17p deletions, without the TP53 mutation, are
less frequent, representing about 10 % of all TP53 alter-
ations [12]. Despite TP53 mutation analysis is becoming
a routine test for CLL patients, inconsistent results may
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be obtained among medical centers, possibly due to the
variety of methods employed. To reduce the interla-
boratory variability, in 2012 the European Research Ini-
tiative on CLL (ERIC) published recommendations
(recently revised and available at http://www.ericll.org/
pages/networks/TP53network) concerning several meth-
odologies suitable for TP53 analysis [13]. Two principal
methodological procedures are suggested for TP53 muta-
tion detection: Sanger Sequencing or Next Generation Se-
quencing (NGS). Generally, at least exons from the fourth
to the ninth, including splicing sites, should be covered in
the analysis, even if the optimal range goes from the sec-
ond to the eleventh. According to the ERIC recommenda-
tions on sensitivity threshold, only mutations detectable
by Sanger sequencing and mutations with an allelic frac-
tion higher than 10 %, if NGS methods are used, should
be reported.
NGS is a powerful technology, allowing the detection
of many low-rate mutations in potentially every type of
disease and sample, but its major limitation remains the
high initial investment required for the instrumentation
setup. On the other hand, Sanger sequencing is a more
affordable method but it is laborious, time consuming,
and expensive over time. In this scenario, in 2012,
Oxford Nanopore Technologies (ONT) released a port-
able sequencing device known as MinION [14] and in
2014 launched a community-focused access project: the
MinION Access Programme (MAP). MinION is a single-
molecule sequencer connected to a laptop through a USB
3.0 interface. Nanopore technology works by connecting
two strands of DNA molecules by a hairpin, and sequen-
cing them consecutively. During sequencing, the single
strand of DNA passes through biologic nanopores on a
chip, where an electric field is applied and electrical signal
variations of consecutive 5-mers are recorded. DNA bases
are then called using a cloud-based software (Metrichor).
Template and complement sequences obtained are then
used to generate the 2D high quality sequences. Typically,
long reads are produced, up to some dozen kilobases. Due
to the still high error rate, at the moment MinION perfor-
mances cannot be comparable with the previous NGS
platforms. However, the very low costs (estimated by the
company around USD1000 when it will become commer-
cially available), the ease of use, and the length of the
reads, make MinION ideal for screening TP53 mutations,
followed by Sanger sequencing validation.
Methods
Patients
Twelve CLL patients at diagnosis were included in this
study. All cases showed more than 70 % of lymphocytes in
peripheral blood. All except one patient (CLL#7) showed
the TP53 gene deletion in Fluorescence in situ hybridization
(FISH) experiments, performed as previously reported
[15, 16]. The main clinical and biological features of these
patients are reported in Table 1. All 12 samples were ana-
lyzed by Sanger and MinION in blinded manner.
Sanger sequencing
All samples were analyzed by direct Sanger sequencing
according to the International Agency for Research on
Cancer (IARC) protocol (http://p53.iarc.fr/Download/
TP53_DirectSequencing_IARC.pdf ). Electropherograms
were then analyzed by visual inspection, glass free
software for Sanger analysis data (http://shiny.bat.inf
spire.org/igcllglass/) and GeneScreen [17].
TP53 Amplification and barcoding
Genomic DNA was extracted from peripheral blood using
the QIAamp DNA Blood Mini Kit (Qiagen) and quantified
with Qubit 2.0 Fluorometer (Life Technologies).
According to the Oxford Nanopore Barcoding protocol
for amplicons (Version DK003_1148_revB_12Feb2015),
for each patient, we performed a Long-PCR using the
Table 1 Patients clinical data and reads mapping statistics
Patient Sex/Age FISH IgVH status Stage (Binet) Total 2D reads count TP53 mapped reads
CLL#1 F/62 del(17)(p13), del(13)(q14) Unmutated A 329 217
CLL#2 M/59 del(17)(p13), del(13)(q14) Unmutated B 307 173
CLL#3 M/59 del(17)(p13), del(13)(q14) Unmutated A 210 104
CLL#4 M/63 del(17)(p13), del(13)(q14) Unmutated A 288 194
CLL#5 F/65 del(17)(p13), del(13)(q14) Mutated A 212 188
CLL#6 M/72 del(17)(p13) Mutated A 342 173
CLL#7 F/30 del(13)(q14) Unmutated A 220 208
CLL#8 M/64 del(17)(p13), del(13)(q14) Unmutated B 154 135
CLL#9 M/56 del(17)(p13), del(13)(q14), del(11)(q22), +12 Unmutated B 147 135
CLL#10 F/72 del(17)(p13), del(13)(q14) Unmutated B 197 90
CLL#11 F/45 del(17)(p13), del(13)(q14) Unmutated B 147 120
CLL#12 F/65 del(17)(p13), del(13)(q14) Mutated A 119 113
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PrimeSTAR GXL DNA Polymearse (Takara Bio Inc.),
two tailed primers (PreBAR_P-559 5’-TTTCTGT
TGGTGCTGATATTGCTCTCATGCTGGATCCCCAC
T-3’ and PreBAR_P-E11Re 5’-ACTTGCCTGTCGCTC
TATCTTCTGACGCACACCTATTGCAAG-3’), 180 ng
of genomic DNA, in a final volume of 25 μl. Thermal-
cycling conditions were 98 °C for 10 s, 68 °C for 8 min
(30 cycles) and 4 °C hold. The PCR products, visualized
on an agarose-gel (1 %), were purified using the QIAquick
PCR Purification Kit (Qiagen), and used as templates
for the Barcoding PCR. Barcoding was performed
with the same Polymerase and 12 different pairs of
Barcoding primers from ONT, BC01-BC12, in a final
volume of 50 μl. Thermal-cycling conditions were
98 °C for 10 s, 62 °C for 15 s, 68 °C for 8 min (15 cycles)
and 4 °C hold.
Minion library preparation and sequencing
Before starting library preparation, we purified, quanti-
fied and estimated the purity of samples (Nanodrop).
Two mixes were then prepared, each pulling six bar-
coded amplicons at equal weight ratio. One microgram
of each pool was diluted to 80 μl in nuclease-free water
and prepared for sequencing. According to the ONT
Sequencing protocol (SQK-MAP005), DNA was end-
repaired with the NEBNext End Repair Module (New
England Biolabs Inc.) and subsequently dA-tailed using
the NEBNext dA-Tailing Module (New England Biolabs
Inc.), prior to ligation of nanopore-specific adapters with
Blunt/TA Ligase Master Mix (New England Biolabs
Inc.). All purifications were performed with Agencourt
AMPure XP beads (Beckman Coulter Inc.). Dynabeads
His-Tag Isolation & Pulldown (Life Technologies) was
used to elute the library in the pre-sequencing Mix.
After the Platform QC run, sequencing mix (75 μl of 2X
Running Buffer, 66 μl of nuclease-free water, 3 μl of Fuel
Mix and 6 μl of the Pre-sequencing Mix) was loaded
and the MAP_48Hr_Sequencing_Run.py protocol was
started (MinION flowcell: FLO-MAP003; MinKNOW
software: v48.2.14). During running, two reloads of the
sequencing mix were performed and the run was
stopped after 24 h.
Data analysis
PoRe R package was used to obtain summary informa-
tion about the sequencing data, as well as to extract
FASTA files from FAST5 files [18].
The NanoOK package was employed for coverage and
error assessment, using the TP53 genomic sequence
NC_000017.10 as reference [19].
Finally, Galaxy, a web-based platform for processing NGS
data, was employed for variant analysis (https://usegalaxy
.org/), [20–22]. Reads were aligned on GRCh37 human ref-
erence genome with the BWA-MEM method [23] using
specific Nanopore platform parameters (https://github.com/
lh3/bwa/blob/master/NEWS.md/#release-079-19-may-2014)
and visualized with the Integrative Genomics Viewer
(IGV) browser [24, 25]. Single nucleotide variants (SNV)
and insertions/deletions (indels) detection was separately
performed with the Varscan software [26], and VCF files
were filtered and annotated with the gene variation IARC
TP53 database (v. R17). In particular, for SNV detection,
the minimum read depth and supporting reads parame-
ters were set according to the lowest mean coverage
(minimum read depth of 50, minimum supporting reads
of 10). Whereas, for indels detection, the minimum read
depth and the minimum supporting reads values were set
at 50 and 13, respectively. The minimum variant allele fre-
quency threshold and p-value threshold for variant calling
were 0.01 and 0.05, respectively, in all Varscan analyses.
Results
TP53 mutation analysis by Sanger sequencing
All patients included in our study were investigated for
TP53 mutation by Sanger sequencing, according with
the IARC protocol.
In the attempt of increasing our analytical sensitivity, we
decided to test the MinION performance on selected CLL
cases bearing the 17p deletion. As assessed by FISH, 11/12
patients carried the 17p deletion, and among them, 4 also
had a TP53 mutation (Tables 1 and 3). Reportedly [10],
there is a high chance to find TP53 mutations in patients
with the 17p deletion, thus supporting our decision in case
selection.
TP53 mutation analysis by MinION sequencing
TP53 gene was amplified from genomic DNA in a single
Long PCR reaction. Amplicons, spanning from exon 2
to exon 11 (7150 bp), were then barcoded and loaded on
MinION for sequencing.
A total of two runs were performed, employing two li-
braries of six patients each one and two different flowcells,
with 316 and 401 active pores respectively. For both ex-
periments, 22421 fast5 total files were produced, contain-
ing raw electric signals. After base-calling in Metrichor,
each run generated 14Mbases and 24Mbases. Finally, of
the total reads produced, 3619 passed 2D filters and 2652
had a recognizable barcode (Table 2). In general, 2D pass
reads had a length spanning from 150 bp to 7200 bp with
a mean of around 4 Kb. Plotting the distribution of read
lengths, we could observe a prevalent peak around 7 Kb,
in agreement with our amplicon size (Fig. 1). Shorter
reads, likely originating from breaks during purifications
or library preparation, were observed as well.
Data analysis and error correction
Nanopore sequencing is a relative young technology and
despite the rapid technical improvements, is still affected
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by a high error rate (estimated around 10 %), posing a
problem in SNV analysis. To date, the only data on hu-
man gene variant analysis from MinION sequencing re-
gard the detection of structural variants in cancer [27].
Among the several methods proposed to limit the
error rate, we tested two in silico strategies: the Nano-
correct correction pipeline, specific for Nanopore data
[28], and the more generic ALEC (Amplicon Long-read
Error Correction) python script [29].
Nanocorrect is a pipeline inspired by pbdagcon
(https://github.com/PacificBiosciences/pbdagcon) which
uses DALIGNER (https://github.com/thegenemyers/DA
LIGNER) and poa [30] to correct sequencing errors in
Nanopore reads. ALEC script has been originally devel-
oped for processing PacBio raw data to correct random
sequencing errors specifically on long amplicons using
alignment information from the SAM files [29].
After demultiplexing, reads were analyzed before and
after error correction with NanoOK (Additional file 1:
Table S1). A mean error rate of 15 % on mean values per
100 aligned bases counted including indels was detected
before correction (raw reads), whereas the mean error rate
dropped to 4-5 % after correction with nanocorrect and
ALEC. Furthermore, separate error rate analysis for inser-
tions, deletions and substitutions highlighted higher values
for deletions. Mean insertion/deletion size reported was
1-2 nucleotides.
Coverage analyses showed that the TP53 sequence,
from exon 2 to exon 11, introns included, was com-
pletely and uniformly covered in each patient (Fig. 2).
Moreover, as compared to Nanocorrect corrected reads,
raw data and ALEC corrected data generally produced
higher coverage rates, although the minimum coverage
value was never below 50x.
Variant calling and annotation
Read mapping, variant calling, annotation with “gene
variation IARC TP53 database”, and variant filtering
were performed with Galaxy starting from both raw
reads and corrected reads. We created a complete work-
flow available TP53 at https://usegalaxy.org/u/ematlab/w/
tp53-mutation-screening-filtering to use with a re-
formatted file of “gene variation IARC TP53 database”
(Additional file 2: File S2). After analysis the workflow
Table 2 Reads summary from MinION sequencing
Read type Number of reads Minimum length (bp) Max length (bp) Mean length (bp)
Pass 1D Template 3619 186 7607 4209
1D complement 3619 173 7821 4047
2D consensus 3619 176 7209 4170
Fail 1D Template 18319 5 199114 3407
1D complement 7926 9 123134 3552
2D consensus 4195 115 73841 3991
Fig. 1 Reads length distribution plot
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outputs two files for SNV and Indels already filtered
against TP53 mutation IARC database.
Variant filtering
Excluding intronic non-affecting splicing and exonic si-
lent variations, analyses with raw reads returned the
highest number of variants, especially for SNV. Con-
versely, the most stringent output was obtained from
variant calling performed on nanocorrect corrected
reads. Results were further filtered by Sanger sequencing
detection limit, set around 15 % for SNV and 20 % for
indels due to the higher error rate observed for deletions
(Additional file 1: Table S1).
To evaluate whether recurrent sequencing errors
could occur because of the nature of the sequences, thus
producing false positives results, we checked if same var-
iants were called in different patients. We found some
recurrent variants both in samples sequenced on the
same flowcell and on different flowcells, and therefore
we decided also to filter variants by recurrence, consid-
ering the low chance to find the same mutation in more
than one sample simultaneously.
Comparing the results obtained from corrected and un-
corrected reads after filtering, we found 24 unique variants
called from uncorrected reads, and 17 and 8 called from
ALEC and nanocorrect corrected reads respectively.
Fig. 2 Coverage plots from corrected and uncorrected (Raw) reads after mapping on TP53 genomic sequence
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A final summary of mutations detected with all methods
we used and their comparison is shown in Table 3.
In general, all mutations detected by Sanger sequen-
cing were also detected starting from raw reads and
ALEC corrected reads. Additionally, for patient CLL#12,
one mutation previously not detected by automated elec-
tropherogram analysis, was instead detected by visual in-
spection after the indications generated from MinION
(Fig. 3, Table 3 and Additional file 3: Fig S3). Nanocorrect
corrected reads produced two false negatives, namely in
CLL#8 and CLL#12 (Table 3).
As expected, all recurrent variants resulted as false
positive.
Discussion
The MinION measures changes in electrical current as
individual strands of DNA pass through one of its 500
protein tiny pores. To date, it is the only technology that
directly measures a single DNA strand rather than in-
corporation events relative to a template strand. More-
over, speed, single-base sensitivity, and long read lengths
make nanopores a promising technology for high-
throughput sequencing [14, 31, 32]. In particular, the
ability to generate long reads may help to resolve repeat
regions within the genome that are challenging for
short-read platforms; in fact, it has been recently dem-
onstrated that MinION is able to determine the number
Table 3 Genomic and protein description of mutations detected by Sanger and MinION sequencing
Patient Genomic description Protein description Exon/Intron Functional Domain Mutation
frequencya
Raw Readsb ALECc Nanocorrectc
CLL#2 g.7577144A > G p.Leu265Pro 8-exon DNA binding 34 % 38.6 % 39.13 % 78.72 %
CLL#8 g.7577548C > T p.Gly245Ser 7-exon DNA binding 31 % 26.9 % 30.28 % ND
CLL#10 g.7577121_7577122GC > TT p.Arg273Ser 8-exon DNA binding 58 % 41.5 % 61.29 % 93.55 %
CLL#11 g.7577501del p.Ser261Valfsb84 7-exon DNA binding 46 % 39.7 % 44.21 % 35.48 %
CLL#12 g.7578406C > T p.Arg175His 5-exon DNA binding ND 18.3 % 16.67 % ND
ND not detected
aPercentage calculated from electropherograms using glass
bFrequency calculated starting from non-corrected reads
cFrequency calculated starting corrected reads
Fig. 3 Example of mutations detected in two samples (CLL#8 and CLL#12). The mutation detected in CLL#8 was not found from nanocorrect
corrected reads. CLL#12 mutation was detected only from the analysis with raw and ALEC corrected reads. The same mutation was barely visible
in Sanger sequencing. Aligned reads are visualized by IGV
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of repeats in the human X chromosome repeat region
using spanning reads of 42 Kbp [33]. This feature makes
nanopore-based technology potentially very suitable for
the targeted sequencing of cancer-relevant gene muta-
tions. The only limitation of MinION technology is error
proneness, an issue that can be moderated by several
error correction bioinformatics methods.
In the present work we report the first use of MinION
to detect TP53 mutations in CLL patients. The recom-
mended method to assess TP53 mutation status is stand-
ard Sanger sequencing; pre-screening techniques such as
denaturing high-performance liquid chromatography
(dHPLC) or single-strand conformation analysis poly-
morphism (SSCP) could be performed to reduce time
and costs. In any case results have to be confirmed by
Sanger sequencing in order to identify the nature of
mutation.
TP53 mutation analysis in CLL patients is particularly
challenging considering that TP53 aberrations are infre-
quent at the time of initial chemotherapy, but increase
their prevalence in multiply relapsed, chemotherapy-
refractory populations [6, 8]. Therefore, monitoring
TP53 status after the first line treatment or at CLL re-
lapse is of considerable importance in order to plan the
best treatment option for the patient.
Using our version of MinION (MIN-MAP001) we de-
veloped a workflow (Fig. 4) for read error correction to-
gether with a variant calling pipeline that considerably
reduce the false positive variants, thus improving the
overall performance. In our hands, the nanopore-based
technology has proven to be a useful tool for TP53 mu-
tation detection. From a practical point of view, in the
context of TP53 mutational analysis, we suggest that
MinION sequencing could be ideal in a pre-screening
step, with several advantages compared to the current
methods. Additionally, MinION pre-screening approach
requires only two PCR per patient (TP53 long amplifica-
tion and barcoding) instead of one PCR per exon. The
obtained results are more informative in comparison to
those obtained with other pre-screening methods, poten-
tially making the subsequent Sanger interpretation easier
and more sensitive. Anyway at the state of the art of this
Fig. 4 Schematic workflow implemented for TP53 mutational analysis
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technology, from a clinically point of view we recommend
to comply at the ERIC reporting guidelines for Sanger se-
quencing (http://www.ericll.org/pages/networks/tp53net
work/ericmanualfortp53mutationalanalysis).
As mentioned, one of the major drawbacks is the
high error rate that might lead to an elevated number
of false positive variants. To limit this error, we tested
two different in silico methods for reads correction:
nanocorrect and ALEC, and applied additional filters
on the variants called, such as IARC annotation, mu-
tation effect, allelic frequency and recurrence. Mainly,
recurrence was the most effective filter to reduce false
positives rate, but required multiple samples to be
performed.
As regards error correction methods, nanocorrect
strongly reduced the final variants called, although pro-
duced some false negatives. Conversely, raw reads did
not return false negative but too many false positives
were called. The best results were obtained by ALEC,
which returned no false negatives and a very limited
number of false positives.
Finally, a relevant advantage of MinION is its limited
costs. Excluding device charge, that is estimated
around USD1000, we calculated that, if 6 samples are
contemporarily run in a flowcell, the cost per sample is
around USD180 a price comparable to that of Sanger
sequencing. Moreover, since very high coverages were
reached in our analyses, we believe that the overall
costs could be further reduced by running more sam-
ples per flowcell.
Conclusions
In summary, we demonstrate that MinION is a suitable
tool for the detection of TP53 gene mutations in pa-
tients affected by CLL, and propose that its low costs
and ease of use may potentially expand its field of
applications to other cancer genes. At the moment
MinION is still not adequate for substituting Sanger se-
quencing nor other NGS technologies, but can be a
useful strategy for pre-screening analyses. Finally, the
constant improvements of nanopore technology prom-
ise an exclusive and convenient use of MinION in the
immediate future.
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mutation. (TIF 3259 kb)
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